University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Hospital


Location: Leuven, Belgium (BE) BE

ISNI: 0000000406263338

ROR: https://ror.org/0424bsv16

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study (2021) Dommasch M, Steger A, Barthel P, Huster KM, Mueller A, Sinnecker D, Laugwitz KL, et al. Journal article Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study (2021) Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial (2021) Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Rech J, et al. Journal article PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives (2021) Gevaert T, Cimadamore A, Montironi R, Eckstein M Journal article Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers (2021) Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, et al. Journal article Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database (2021) Hannoun-Levi JM, Gal J, Van Limbergen E, Chand ME, Schiappa R, Smanyko V, Kauer-Domer D, et al. Journal article